Viracta Therapeutics (VIRX) News Today $0.25 +0.02 (+7.43%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Viracta Therapeutics Highlights Strategic Focus and FinancialsNovember 15, 2024 | markets.businessinsider.comViracta Therapeutics, Inc.: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deViracta Therapeutics expects cash to fund operations into Q1 of 2025November 13, 2024 | markets.businessinsider.comViracta Therapeutics reports Q3 EPS (27c) vs (33c) last yearNovember 13, 2024 | markets.businessinsider.comViracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | globenewswire.comViracta Therapeutics reports 42% reduction in force, strategic reprioritizationNovember 7, 2024 | markets.businessinsider.comViracta Therapeutics (NASDAQ:VIRX) Stock, Short Interest ReportOctober 29, 2024 | benzinga.comViracta Therapeutics (NASDAQ:VIRX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comViracta Therapeutics (NASDAQ:VIRX) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comViracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | markets.businessinsider.comLeerink Partners Downgrades Viracta Therapeutics (VIRX)August 17, 2024 | msn.comVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024August 14, 2024 | msn.comViracta Therapeutics, Inc.: Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deViracta jumps after corporate updateAugust 14, 2024 | msn.comWhy Is Viracta Therapeutics (VIRX) Stock Up 42% Today?August 14, 2024 | investorplace.comViracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comViracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development PlanAugust 14, 2024 | globenewswire.comOppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 23, 2024 | markets.businessinsider.comViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement GrantsMay 18, 2024 | finanznachrichten.deViracta Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comViracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerMay 14, 2024 | globenewswire.comRBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 10, 2024 | markets.businessinsider.comVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024May 10, 2024 | investorplace.comViracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | globenewswire.comDay One wins FDA nod for brain cancer therapy, OjemdaApril 23, 2024 | msn.comPromising Clinical Trial Results Reinforce Buy Rating for Viracta TherapeuticsApril 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)April 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)April 16, 2024 | markets.businessinsider.comWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?April 15, 2024 | msn.comViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaApril 15, 2024 | globenewswire.comViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanApril 1, 2024 | globenewswire.comViracta Therapeutics CFO and COO Dan Chevallard resignsMarch 22, 2024 | investing.comBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid FinancialsMarch 12, 2024 | markets.businessinsider.comVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023March 8, 2024 | msn.comViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 7, 2024 | globenewswire.comViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialFebruary 29, 2024 | globenewswire.comVIRX Mar 2024 2.500 callFebruary 17, 2024 | finance.yahoo.comViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finance.yahoo.comViracta Therapeutics Provides Clinical Update and Outlook for 2024January 4, 2024 | finance.yahoo.comViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and DatesDecember 22, 2023 | benzinga.comViracta gets orphan drug status for Nana-val for EBV tumorsDecember 12, 2023 | msn.comViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaDecember 12, 2023 | finance.yahoo.comViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsDecember 4, 2023 | finance.yahoo.comViracta Therapeutics Inc VIRXNovember 18, 2023 | morningstar.comViracta Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | benzinga.comViracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical AdvancesNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.comPromising Developments in Viracta Therapeutics Research and Trials Bolster Buy RatingOctober 5, 2023 | markets.businessinsider.comViracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersOctober 4, 2023 | finance.yahoo.com Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE! 👉 Yes, I Want the Free Report! 👈 VIRX Media Mentions By Week VIRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRX News Sentiment▼0.000.59▲Average Medical News Sentiment VIRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRX Articles This Week▼00▲VIRX Articles Average Week Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OKYO News DTIL News ELEV News OTLK News LTRN News ANEB News VRCA News MRKR News BCAB News RNXT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
